ImmuPharma (LON:IMM) Shares Up 4.9% – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report) shares traded up 4.9% during mid-day trading on Saturday . The company traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.67 ($0.04). 109,382,164 shares traded hands during mid-day trading, an increase of 245% from the average session volume of 31,664,631 shares. The stock had previously closed at GBX 3.50 ($0.04).

ImmuPharma Price Performance

The company’s 50 day simple moving average is GBX 1.40 and its 200 day simple moving average is GBX 1.65. The company has a market capitalization of £15.30 million, a PE ratio of -367.30 and a beta of 1.53.

About ImmuPharma

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

See Also

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.